Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell–killing capability
Eliana Ribechini, Ina Eckert, Andreas Beilhack, Nelita Du Plessis, Gerhard Walzl, Ulrike Schleicher, Uwe Ritter, Manfred B. Lutz
Eliana Ribechini, Ina Eckert, Andreas Beilhack, Nelita Du Plessis, Gerhard Walzl, Ulrike Schleicher, Uwe Ritter, Manfred B. Lutz
View: Text | PDF
Research Article Immunology Infectious disease

Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell–killing capability

  • Text
  • PDF
Abstract

Tuberculosis patients and mice infected with live Mycobacterium tuberculosis accumulate high numbers of myeloid-derived suppressor cells (MDSCs). Here, we hypothesized that dead M. tuberculosis vaccines also may induce MDSCs that could impair the efficacy of vaccination. We found that repeated injections of M. tuberculosis vaccines (heat-killed M. tuberculosis in incomplete Freund’s adjuvant, such as Montanide) but not single or control vaccines without M. tuberculosis strongly expanded CD11b+ myeloid cells in the spleen, leading to T cell suppression of proliferation and killing ex vivo. Dead M. tuberculosis vaccination induced the generation of CD11b+Ly6ChiCD115+ iNOS/Nos2+ monocytic MDSCs (M-MDSCs) upon application of inflammatory or microbial activation signals. In vivo these M-MDSCs were positioned strategically in the splenic bridging channels and then positioned in the white pulp areas. Notably, within 6–24 hours, in a Nos2-dependent fashion, they produced NO to rapidly kill conventional and plasmacytoid DCs while, surprisingly, sparing T cells in vivo. Thus, we demonstrate that M. tuberculosis vaccine induced M-MDSCs do not directly suppress effector T cells in vivo but, instead, indirectly by killing DCs. Collectively, we demonstrate that M. tuberculosis booster vaccines induce M-MDSCs in the spleen that can be activated to kill DCs. Our data suggest that formation of MDSCs by M. tuberculosis vaccines should be investigated also in clinical trials.

Authors

Eliana Ribechini, Ina Eckert, Andreas Beilhack, Nelita Du Plessis, Gerhard Walzl, Ulrike Schleicher, Uwe Ritter, Manfred B. Lutz

×

Figure 1

CFA administration induces myeloid cell expansion and accumulation in the splenic red pulp.

Options: View larger image (or click on image) Download as PowerPoint
CFA administration induces myeloid cell expansion and accumulation in th...
(A) General scheme of single and repetitive immunizations. Mice received a single s.c. dose of CFA at day 0 alone or second dose of IFA or CFA at day 12. Then spleens were analyzed at day 15. Optionally, mice were challenged with LPS/IFN-γ at day 15 for 6 hours or 24 hours before spleens were further analyzed. (B) C57BL/6 mice were injected s.c. with CFA or CFA/CFA or remained untreated before spleens were analyzed according the scheme in A. Spleen cellularity was counted at day 15 (9 independent experiments with replicates: Ctrl = 14, CFA = 19, CFA/CFA = 21). (C) Mice were injected as described above, and spleen cells were analyzed by FACS for Ly6C+ and Ly6G+ cell subsets. Numbers above the dot plots represent the percentages of the red gated Ly6Chi gated cells or the top right quadrant for Ly6G+ cells (4 independent experiments with replicates: Ctrl = 9, CFA = 14, CFA/CFA = 11). (D) Spleens from the indicated mice were collected at day 15 and cryosections were stained for Gr-1 for myeloid cells and B220 to indicate B cell zones as borders of the white pulp. Scale bars: 500 μm. Microscopy data are representative of at least 3 independent experiments with (n = 3 mice) for each group. (B and C) Statistical significance was assessed by comparison of control versus treated mice. Statistics by 1-way ANOVA with multiple comparisons and Tukey’s post test. **P < 0.01, ***P <0.005, ****P < 0.0001. Values correspond to the mean ± SD.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts